Skip to main content

ORIGINAL RESEARCH article

Front. Oncol., 29 October 2020
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 10 - 2020 | https://doi.org/10.3389/fonc.2020.569584
This article is part of the Research Topic Novel Diagnostic and Therapeutic Strategies in the Management of Cerebral Gliomas View all 55 articles

RETRACTED: LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT

Retracted

A retraction of this article was approved in:

  1. Retraction: LOXL2 upregulation in gliomas drives tumorigenicity by activating autophagy to promote TMZ resistance and trigger EMT

    1. Read retraction
Qing ZhangQing Zhang1Lianhe YangLianhe Yang2Gefei GuanGefei Guan1Peng ChengPeng Cheng1Wen ChengWen Cheng1Anhua Wu*Anhua Wu1*
  • 1Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, China
  • 2Department of Pathology, First Affiliated Hospital and College of Basic Medical Sciences of China Medical University, Shenyang, China

This article has been retracted. Please follow the link to the full retraction notice for details.

Citation: Zhang Q, Yang L, Guan G, Cheng P, Cheng W and Wu A (2020) LOXL2 Upregulation in Gliomas Drives Tumorigenicity by Activating Autophagy to Promote TMZ Resistance and Trigger EMT. Front. Oncol. 10:569584. doi: 10.3389/fonc.2020.569584

Received: 04 June 2020; Accepted: 05 October 2020;
Published: 29 October 2020; Retracted: 27 August 2024.

Edited by:

Maria Caffo, University of Messina, Italy

Reviewed by:

Xin Shang, Shandong University, China
Shweta Tiwary, National Institutes of Health (NIH), United States

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.